Literature DB >> 30129977

Fluid Dynamics in the HeartMate 3: Influence of the Artificial Pulse Feature and Residual Cardiac Pulsation.

Lena Wiegmann1, Bente Thamsen2,3,4, Diane de Zélicourt1,3, Marcus Granegger2, Stefan Boës4, Marianne Schmid Daners4, Mirko Meboldt4, Vartan Kurtcuoglu1,5,6.   

Abstract

Ventricular assist devices (VADs), among which the HeartMate 3 (HM3) is the latest clinically approved representative, are often the therapy of choice for patients with end-stage heart failure. Despite advances in the prevention of pump thrombosis, rates of stroke and bleeding remain high. These complications are attributed to the flow field within the VAD, among other factors. One of the HM3's characteristic features is an artificial pulse that changes the rotor speed periodically by 4000 rpm, which is meant to reduce zones of recirculation and stasis. In this study, we investigated the effect of this speed modulation on the flow fields and stresses using high-resolution computational fluid dynamics. To this end, we compared Eulerian and Lagrangian features of the flow fields during constant pump operation, during operation with the artificial pulse feature, and with the effect of the residual native cardiac cycle. We observed good washout in all investigated situations, which may explain the low incidence rates of pump thrombosis. The artificial pulse had no additional benefit on scalar washout performance, but it induced rapid variations in the flow velocity and its gradients. This may be relevant for the removal of deposits in the pump. Overall, we found that viscous stresses in the HM3 were lower than in other current VADs. However, the artificial pulse substantially increased turbulence, and thereby also total stresses, which may contribute to clinically observed issues related to hemocompatibility.
© 2018 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Keywords:  Artificial pulse; Cardiac cycle; Computational fluid dynamics; HeartMate 3; Hemocompatibility; Ventricular assist devices

Mesh:

Year:  2018        PMID: 30129977     DOI: 10.1111/aor.13346

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  6 in total

Review 1.  Physiology of the Assisted Circulation in Cardiogenic Shock: A State-of-the-Art Perspective.

Authors:  Julien Guihaire; Francois Haddad; Mita Hoppenfeld; Myriam Amsallem; Jeffrey W Christle; Clark Owyang; Khizer Shaikh; Joe L Hsu
Journal:  Can J Cardiol       Date:  2019-11-09       Impact factor: 5.223

2.  Novel Acoustic Biomarker of Quality of Life in Left Ventricular Assist Device Recipients.

Authors:  Boyla O Mainsah; Priyesh A Patel; Xinlin J Chen; Cameron Olsen; Leslie M Collins; Ravi Karra
Journal:  J Am Heart Assoc       Date:  2021-03-04       Impact factor: 5.501

Review 3.  Device-Induced Hemostatic Disorders in Mechanically Assisted Circulation.

Authors:  Shigang Wang; Bartley P Griffith; Zhongjun J Wu
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

4.  Insights Into the Low Rate of In-Pump Thrombosis With the HeartMate 3: Does the Artificial Pulse Improve Washout?

Authors:  Peng Fang; Jianjun Du; Andrea Boraschi; Silvia Bozzi; Alberto Redaelli; Marianne Schmid Daners; Vartan Kurtcuoglu; Filippo Consolo; Diane de Zélicourt
Journal:  Front Cardiovasc Med       Date:  2022-03-11

5.  Validation of a Miniaturized Test Loop for the Assessment of Human Blood Damage by Continuous-Flow Left-Ventricular Assist Devices.

Authors:  Eva Woelke; Ilona Mager; Thomas Schmitz-Rode; Ulrich Steinseifer; Johanna C Clauser
Journal:  Ann Biomed Eng       Date:  2021-08-24       Impact factor: 3.934

6.  The role of renin-angiotensin system in patients with left ventricular assist devices.

Authors:  Alexandros Briasoulis; Ernesto Ruiz Duque; Dimitrios Mouselimis; Anastasios Tsarouchas; Constantinos Bakogiannis; Paulino Alvarez
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Oct-Dec       Impact factor: 1.636

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.